Over the last few years, Recent surveys show that about one in every eight adults in the United States or 12% are currently taking a GLP-1 medication like Wegovy or Zepbound for weight loss or treatment of a chronic condition
Lead author John Deanfield, professor of cardiology at the UCL Institute of Cardiovascular Science, said: Abdominal fat is more dangerous for our cardiovascular health than overall weight, and therefore it is not surprising to see a link between reduction in waist size and cardiovascular benefit
Take Control of Your Health Today Losing weight can be challenging, but you dont have to do it alone
Yes, many protocols combine both methods for comprehensive benefits
These agents include semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Victoza, Saxenda), among others
Can I join a retatrutide clinical trial in the UK